Sarepta Stock Surges as FDA Reauthorizes Elevidys Shipments
Sarepta's stock surged after the FDA allowed the company to resume shipments of its gene therapy drug Elevidys for Duchenne muscular dystrophy, following a voluntary pause for safety review. The stock closed up 14.2%, though it has declined significantly this year.